Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02263898
Title Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Jonsson Comprehensive Cancer Center
Indications

melanoma

Therapies

Binimetinib + Encorafenib

Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST